Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Avtozma 20 mg/mL concentrate for solution for infusion
Medicines register · Ireland

Avtozma 20 mg/mL concentrate for solution for infusion

Authorisation EU/1/24/1896/001-006 · Celltrion Healthcare Hungary Kft.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Celltrion Healthcare Hungary Kft. (all products →)
Active substance
Tocilizumab
Clinical trials
75 clinical trials →
Dosage form
Concentrate for solution for infusion
Route of administration
Intravenous use
ATC code
L04AC07
First authorised
14/02/2025
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Tocilizumab: supply and approvals

13 authorised products on the HPRA list contain Tocilizumab. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
RoActemra: Shortage resolved, first published 3 Sep 2021
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)
Recent EMA authorisation
Tuyory, 27 Apr 2026 (biosimilar), Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1896. It has been authorised for 1 year (since 14 February 2025). The HPRA list does not say whether it is on sale.

Open the European Commission’s Union Register record →

Other medicines with Tocilizumab in Ireland

12 other products on the HPRA list contain Tocilizumab, from 5 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Avtozma 162 mg solution for injection in pre-filled penCelltrion Healthcare Hungary Kft.Centralised EU authorisationNot stated
Avtozma 162 mg solution for injection in pre-filled syringeCelltrion Healthcare Hungary Kft.Centralised EU authorisationNot stated
RoActemra 162 mg Solution for injectionRoche Registration GmbHCentralised EU authorisationNot stated
RoActemra 162 mg Solution for injectionRoche Registration GmbHCentralised EU authorisationNot stated
RoActemra 20 mg/ml Concentrate for solution for infusionRoche Registration GmbHCentralised EU authorisationNot stated
Tofidence 20 mg/ml Concentrate for solution for infusionStada Arzneimittel AGCentralised EU authorisationNot stated
Tuyory 162 mg solution for injection in pre-filled penGedeon Richter PlcCentralised EU authorisationNot stated
Tuyory 162 mg solution for injection in pre-filled syringeGedeon Richter PlcCentralised EU authorisationNot stated
Tuyory 20 mg/mL concentrate for solution for infusionGedeon Richter PlcCentralised EU authorisationNot stated
Tyenne 162 mg solution for injection in pre-filled penFresenius Kabi Deutschland GmbHCentralised EU authorisationNot stated
Tyenne 162 mg solution for injection in pre-filled syringeFresenius Kabi Deutschland GmbHCentralised EU authorisationNot stated
Tyenne 20 mg/mL concentrate for solution for infusionFresenius Kabi Deutschland GmbHCentralised EU authorisationNot stated

The licence holder

Celltrion Healthcare Hungary Kft. holds 30 products on the HPRA list, with 10 different active substances; 0 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.